​

BridgeBio Pharma (BBIO) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

BridgeBio Pharma Revenue Highlights

Latest Revenue (Y)

$221.90M

Latest Revenue (Q)

$71.50M

Main Segment (Y)

License

Main Geography (Y)

License

BridgeBio Pharma Revenue by Period

BridgeBio Pharma Revenue by Year

DateRevenueChange
2024-12-31$221.90M2285.27%
2023-12-31$9.30M-88.02%
2022-12-31$77.65M11.38%
2021-12-31$69.72M745.14%
2020-12-31$8.25M-79.66%
2019-12-31$40.56M100.00%
2018-12-31-100.00%
2017-12-31--

BridgeBio Pharma generated $221.90M in revenue during NA 2024, up 2285.27% compared to the previous quarter, and up 547.10% compared to the same period a year ago.

BridgeBio Pharma Revenue by Quarter

DateRevenueChange
2025-06-30$71.50M-38.70%
2025-03-31$116.63M1882.88%
2024-12-31$5.88M115.30%
2024-09-30$2.73M26.01%
2024-06-30$2.17M-98.97%
2024-03-31$211.12M11998.57%
2023-12-31$1.75M-57.35%
2023-09-30$4.09M149.30%
2023-06-30$1.64M-10.13%
2023-03-31$1.83M-2.35%
2022-12-31$1.87M453.25%
2022-09-30$338.00K-99.54%
2022-06-30$73.75M4253.36%
2022-03-31$1.69M-86.85%
2021-12-31$12.89M449.74%
2021-09-30$2.34M-95.66%
2021-06-30$54.02M11593.51%
2021-03-31$462.00K278.69%
2020-12-31$122.00K-98.50%
2020-09-30$8.13M100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$13.82M-48.32%
2019-09-30$26.74M100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

BridgeBio Pharma generated $71.50M in revenue during Q2 2025, up -38.70% compared to the previous quarter, and up 33.87% compared to the same period a year ago.

BridgeBio Pharma Revenue Breakdown

BridgeBio Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21Dec 20Dec 19
Product$3.79M--
License$65.92M$8.00M$13.80M

BridgeBio Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 21: License (94.56%), and Product (5.44%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Mar 23Sep 22Jun 22Mar 22Sep 21Jun 21Sep 20
Royalty Revenue$1.62M--------
Net Product Revenue$71.50M$36.74M-------
License and Service--$1.83M$338.00K$73.75M----
Product-----$1.46M$759.00K$987.00K-
License-----$235.00K$1.58M$8.00M-

BridgeBio Pharma's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Net Product Revenue (97.78%), and Royalty Revenue (2.22%).

BridgeBio Pharma Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 19
License$13.80M

BridgeBio Pharma's latest annual revenue breakdown by geography, as of Dec 19: License (100.00%).

Quarterly Revenue by Country

CountryMar 23Sep 22Jun 22Mar 22Sep 21Jun 21Sep 20
License and Service$1.83M$338.00K$73.75M----
Product---$1.46M$759.00K$987.00K-
License---$235.00K$1.58M$8.00M-

BridgeBio Pharma's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).

BridgeBio Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JAZZJazz Pharmaceuticals$4.07B$1.05B
MRNAModerna$3.24B$143.00M
BMRNBioMarin Pharmaceutical$2.85B$776.13M
EXELExelixis$2.17B$568.26M
IONSIonis Pharmaceuticals$705.14M$452.00M
CAICaris Life Sciences$294.01M$100.83M
BBIOBridgeBio Pharma$221.90M$71.50M
MDGLMadrigal Pharmaceuticals$180.13M$212.80M
ROIVRoivant Sciences$124.80M$7.57M
CYTKCytokinetics$18.47M$1.58M
RVMDRevolution Medicines--

BBIO Revenue FAQ

What is BridgeBio Pharma’s yearly revenue?

BridgeBio Pharma's yearly revenue for 2024 was $221.9M, representing an increase of 2285.27% compared to 2023. The company's yearly revenue for 2023 was $9.3M, representing a decrease of -88.02% compared to 2022. BBIO's yearly revenue for 2022 was $77.65M, representing an increase of 11.38% compared to 2021.

What is BridgeBio Pharma’s quarterly revenue?

BridgeBio Pharma's quarterly revenue for Q2 2025 was $71.5M, a -38.70% decrease from the previous quarter (Q1 2025), and a 3198.02% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $116.63M, a 1882.88% increase from the previous quarter (Q4 2024), and a -44.76% decrease year-over-year (Q1 2024). BBIO's quarterly revenue for Q4 2024 was $5.88M, a 115.30% increase from the previous quarter (Q3 2024), and a 237.08% increase year-over-year (Q4 2023).

What is BridgeBio Pharma’s revenue growth rate?

BridgeBio Pharma's revenue growth rate for the last 3 years (2022-2024) was 185.78%, and for the last 5 years (2020-2024) was 2590.05%.

What are BridgeBio Pharma’s revenue streams?

BridgeBio Pharma's revenue streams in c 21 are Product, and License. Product generated $3.79M in revenue, accounting 5.44% of the company's total revenue License generated $65.92M in revenue, accounting 94.56% of the company's total revenue, up 724.04% year-over-year.

What is BridgeBio Pharma’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of BridgeBio Pharma was License. This segment made a revenue of $65.92M, representing 94.56% of the company's total revenue.